

Edgar Filing: SMITH & NEPHEW PLC - Form 6-K

SMITH & NEPHEW PLC  
Form 6-K  
November 27, 2002

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of

-----  
1934  
----

November 27, 2002

Commission File Number 001-14978

SMITH & NEPHEW plc  
(Registrant's name)

15 Adam Street  
London, England WC2N 6LA  
(Address of registrant's principal executive offices)

[Indicate by check mark whether the registrant files or will file  
annual reports under cover Form 20-F or Form 40-F.]

Form 20-F      X                      Form 40-F  
                      -----                      -----

[Indicate by check mark if the registrant is submitting the Form 6-K in paper  
as permitted by Regulation S-T Rule 101(b) (1).]

Yes                      No      X  
                      -----                      -----

[Indicate by check mark if the registrant is submitting the Form 6-K in paper as  
permitted by Regulation S-T Rule 101(b) (7).]

Yes                      No      X  
                      -----                      -----

[Indicate by check mark whether by furnishing the information contained  
in this Form, the registrant is also thereby furnishing information to the  
Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act of  
1934.]

Yes                      No      X  
                      -----                      -----

If "Yes" is marked, indicate below the file number assigned to the  
registrant in connection with Rule 12g3-2 (b) : 82- n/a.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Smith & Nephew plc  
(Registrant)

Date: November 27, 2002

By: /s/ Paul Chambers  
-----  
Paul Chambers  
Company Secretary

2

25 November 2002

Completion of Dermagraft Acquisition

Smith & Nephew, the global advanced medical devices company, announces that it has completed the \$12 million acquisition of the Dermagraft(R) and TransCyte(R) joint venture from Advanced Tissue Sciences, Inc.

Enquiries:

Christopher O'Donnell, Chief Executive  
Smith & Nephew plc

Tel: +44 (0) 20 7401 7646

Peter Hooley, Finance Director  
Smith & Nephew plc

Tel: +44 (0) 20 7401 7646

Angie Craig, Corporate Affairs Director  
Smith & Nephew plc

Tel: +44 (0) 20 7401 7646

David Yates/Jonathan Birt  
Financial Dynamics

Tel: +44 (0) 20 7831 3113

25 November 2002

Edgar Filing: SMITH & NEPHEW PLC - Form 6-K

The Secretary  
London Stock Exchange  
RNS  
Old Broad Street  
London  
EC2N 1HP

Dear Sirs,

Dealing by Director in Ordinary shares of Smith & Nephew plc

We have been informed today that Dudley Eustace, a director of Smith & Nephew plc, has acquired 195 Ordinary shares of the Company at 383.23 pence each on 22 November 2002, through the re-investment of the final dividend paid on 15 November 2002. Mr. Eustace now has a beneficial interest in 49,679 Ordinary shares being 0.0054% of the issued share capital of the Company.

Yours faithfully,

J.V. Sutton  
Assistant Company Secretary